AARTIDRUGS vs HALEOSLABS: Stock Comparison
AARTI DRUGS is the larger company by market capitalisation. AARTI DRUGS shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
AARTIDRUGS leads 8; HALEOSLABS leads 3 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | AARTIDRUGS | HALEOSLABS |
|---|---|---|
| Sector | Healthcare | — |
| Industry | Pharmaceuticals | — |
Price
| Metric | AARTIDRUGS | HALEOSLABS |
|---|---|---|
| Live Price | ₹380.05 | ₹1,611.3 |
| Day Change | -2.2% | 1.74% |
| Volume | 1.59 L | 895 |
| 52-Week High | ₹534 | ₹1,774 |
| 52-Week Low | ₹318.95 | ₹1,181 |
| Distance from 52W High | -28.83% | -9.17% |
Valuation
| Metric | AARTIDRUGS | HALEOSLABS |
|---|---|---|
| Market Cap | ₹3,478 Cr | ₹490 Cr |
| P/E Ratio | 18.19x | 29.35x |
| P/B Ratio | 2.25x | 2.17x |
| EPS | ₹20.93 | ₹8.75 |
| Book Value | ₹169.79 | ₹759.29 |
| Dividend Yield | 0.5% | 0.09% |
Growth
| Metric | AARTIDRUGS | HALEOSLABS |
|---|---|---|
| Revenue Growth (TTM YoY) | 6.4% | 0% |
| EPS Growth (TTM YoY) | -12% | 0% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | AARTIDRUGS | HALEOSLABS |
|---|---|---|
| ROE | 12.05% | 7.75% |
| ROCE | 10.64% | 6.63% |
| Net Margin | 7.6% | 5.33% |
| Operating Margin | 9.19% | 9.48% |
| Debt to Equity | 0.3x | 0.47x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | AARTIDRUGS | HALEOSLABS |
|---|---|---|
| Promoter Holding | 54.07%▼ 0.36 pp | 72.11% |
| FII Holding | 2.26%▲ 0.74 pp | 0% |
| DII Holding | 10.24%▼ 0.05 pp | 0.31% |
| Public Holding | 33.43%▼ 0.32 pp | 27.58% |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AARTI DRUGS and HALEOS LABS.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.